Institute of Pharmacy, Department of Biopharmaceutics and Pharmaceutical Technology, University of Greifswald, Greifswald, Germany.
Eur J Pharm Biopharm. 2010 Oct;76(2):260-8. doi: 10.1016/j.ejpb.2010.06.008. Epub 2010 Jun 19.
The efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2) play an essential role in the limitation of oral bioavailability of drugs. In the last years, pharmaceutical surfactants like cremophor® EL or polysorbate 80 have been shown to interact with ABCB1. However, the knowledge about their influence on ABCC2 is still limited. In this study, the interactions of the nonionic surfactants cremophor® EL, cremophor® RH 40, polysorbate 80, vitamin E TPGS 1000, pluronic® PE 10300 and sucrose ester L-1695 with both efflux transporters were investigated on cellular level. Cell accumulation studies and transport studies were performed using transfected MDCK II cell models. The influence of ABCC2 inhibiting surfactants on the expression level of ABCC2 was also studied. The investigations showed that cremophor® EL, vitamin E TPGS 1000 and higher concentrations of polysorbate 80 inhibit both transporters. Pluronic® PE 10300 and sucrose ester L-1695 inhibit ABCB1 but not ABCC2. Cremophor® RH 40 only shows inhibitory activity on ABCC2. During the investigated incubation period none of the inhibiting surfactants caused an alteration in ABCC2mRNA or protein expression. These findings indicate that the observed interactions are caused by specific inhibition of the transport activity of ABCC2.
外排转运体 ABCB1(p-糖蛋白)和 ABCC2(MRP2)在限制药物的口服生物利用度方面起着重要作用。在过去的几年中,已经表明药物表面活性剂,如 cremophor® EL 或聚山梨酯 80,与 ABCB1 相互作用。然而,关于它们对 ABCC2 的影响的知识仍然有限。在这项研究中,研究了非离子表面活性剂 cremophor® EL、cremophor® RH 40、聚山梨酯 80、维生素 E TPGS 1000、泊洛沙姆 10300 和蔗糖酯 L-1695 与这两种外排转运体在细胞水平上的相互作用。使用转染的 MDCK II 细胞模型进行细胞积累研究和转运研究。还研究了 ABCC2 抑制性表面活性剂对 ABCC2 表达水平的影响。研究表明, cremophor® EL、维生素 E TPGS 1000 和较高浓度的聚山梨酯 80 抑制这两种转运体。泊洛沙姆 10300 和蔗糖酯 L-1695 抑制 ABCB1 但不抑制 ABCC2。 cremophor® RH 40 仅对 ABCC2 显示抑制活性。在研究的孵育期内,没有一种抑制性表面活性剂引起 ABCC2mRNA 或蛋白表达的改变。这些发现表明,观察到的相互作用是由 ABCC2 转运活性的特异性抑制引起的。